ContraFect

ContraFect FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of ContraFect (CFRXQ) as of Oct 19, 2026 is 70.65 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 202.81 % — a change of -65.16% (lower).

FCF Conversion

70.65 %

YoY

-65.16%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of ContraFect is 2022 70.65 % . FCF Conversion Rate (FCF/EBITDA) of ContraFect was 2021 202.81 % . It decreases by -65.16% lower compared to the previous year.

The ContraFect FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2015
88.34 USD
Jan 1, 2016
103.05 USD
Jan 1, 2017
158.05 USD
Jan 1, 2018
70.04 USD
Jan 1, 2019
214.62 USD
Jan 1, 2020
117.86 USD
Jan 1, 2021
202.81 USD
Jan 1, 2022
70.65 USD
The ContraFect FCF Conversion history
YEARFCF ConversionYoY
70.65 %-65.16%
202.81 %+72.07%
117.86 %-45.08%
214.62 %+206.44%
70.04 %-55.69%
158.05 %+53.38%
103.05 %+16.66%
88.34 %+105.80%
42.92 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ContraFect Stock analysis

What does ContraFect do? ContraFect Corp, based in Yonkers, New York, is a clinical-stage biotechnology company focused on developing direct lytic agents (DLAs) such as lysins and amurin peptides to treat life-threatening antibiotic-resistant infections. The company, listed in 2014, employs 23 people and is advancing its lead candidate exebacase (CF-301) for MRSA bloodstream infections and chronic prosthetic joint infections, alongside CF-370 targeting gram-negative bacteria. ContraFect is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ContraFect stock

FCF Conversion Rate (FCF/EBITDA) of ContraFect is 70.65 % in 2022.

FCF Conversion Rate (FCF/EBITDA) of ContraFect changed from 202.81 % to 70.65 %, representing a -65.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) ContraFect since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s ContraFect with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — ContraFect

All Key Metrics — ContraFect